Summary

Glaucoma Therapeutics Market – Scope of Report
TMR’s report on the global glaucoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global glaucoma therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glaucoma therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the glaucoma therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global glaucoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global glaucoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global glaucoma therapeutics market.

The report delves into the competitive landscape of the global glaucoma therapeutics market. Key players operating in the global glaucoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global glaucoma therapeutics market profiled in this report.

Key Questions Answered in Global glaucoma therapeutics Market Report
• What is the sales/revenue generated by glaucoma therapeutics across all regions during the forecast period?
• What are the opportunities in the global glaucoma therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Glaucoma Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global glaucoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global glaucoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global glaucoma therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Therapeutics Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Glaucoma Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2023–2031
6.3.1. Prostaglandins
6.3.2. Beta Blockers
6.3.3. Alpha Agonists
6.3.4. Combination Medications
6.3.5. Cholinergics
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Glaucoma Therapeutics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Ophthalmic Clinics
7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness Analysis, by End-user
8. Global Glaucoma Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Glaucoma Therapeutics Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2023–2031
9.3.1. Prostaglandins
9.3.2. Beta Blockers
9.3.3. Alpha Agonists
9.3.4. Combination Medications
9.3.5. Cholinergics
9.4. Market Value Forecast, by End-user, 2023–2031
9.4.1. Hospitals
9.4.2. Ophthalmic Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast, by Country, 2023–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By End-user
9.6.3. By Country
10. Europe Glaucoma Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2023–2031
10.3.1. Prostaglandins
10.3.2. Beta Blockers
10.3.3. Alpha Agonists
10.3.4. Combination Medications
10.3.5. Cholinergics
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Ophthalmic Clinics
10.4.3. Ambulatory Surgical Centers
10.5. Market Value Forecast, by Country/Sub-region, 2023–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2023–2031
11.3.1. Prostaglandins
11.3.2. Beta Blockers
11.3.3. Alpha Agonists
11.3.4. Combination Medications
11.3.5. Cholinergics
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Ophthalmic Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2023–2031
12.3.1. Prostaglandins
12.3.2. Beta Blockers
12.3.3. Alpha Agonists
12.3.4. Combination Medications
12.3.5. Cholinergics
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Ophthalmic Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2023–2031
13.3.1. Prostaglandins
13.3.2. Beta Blockers
13.3.3. Alpha Agonists
13.3.4. Combination Medications
13.3.5. Cholinergics
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Ophthalmic Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. AbbVie Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Merck & Co., Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Novartis AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Santen Pharmaceutical Co., Ltd.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Bausch Health Companies Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Alcon
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview